| Quantity: | |
|---|---|
Broad model portfolio – IMQ (TLR7/8 agonist), IL-23 (direct Th17 activation), and combination models covering different psoriasis pathways.
Multiple species/strains – C57BL/6, BALB/c mice and Wistar rats available.
Comprehensive endpoints – PASI score, ear thickness, spleen index, body weight, IL-17A levels, skin histopathology (HE).
Translational value – Ideal for testing biologics (anti-IL-17, anti-IL-23), JAK inhibitors, and topical therapies.
IND-ready data packages – Studies can be conducted in accordance with GLP principles.
IMQ Induced C57BL/6 Psoriasis Model
IMQ Induced hIL-17 C57BL/6 transgenic mouse Psoriasis Model
IMQ Induced BALB/c Psoriasis Model
IMQ Induced Wistar Psoriasis Model
IL-23 Induced C57BL/6 Psoriasis Model
IL-23 Induced SD Rat Psoriasis Model
IL-23+IMQ Induced C57BL/6 Psoriasis Model
IL-23+IL-36 Induced C57BL/6 Psoriasis Model
• Efficacy testing of biologics targeting IL-17 (secukinumab, ixekizumab), IL-23 (guselkumab, risankizumab), and TNF-α (etanercept)
• Evaluation of JAK inhibitors (tofacitinib, upadacitinib), PDE4 inhibitors (apremilast), and topical therapies
• Target validation for Th17, IL-23, and TLR pathways in psoriasis
• Biomarker discovery (IL-17A, PASI score, histopathology scoring)
• IND-enabling pharmacology and toxicology studies
Parameter | Specification |
Species/Strains | C57BL/6 mouse, BALB/c mouse, Wistar rat |
Induction methods | Topical IMQ cream (5%) daily for 5–7 days; Intradermal IL-23 injection (single or multiple doses); IMQ + IL-23 combination; IL-23 + IL-36 combination |
Study duration | 5–14 days (IMQ models); 3–7 days (IL-23 models) |
Key endpoints | PASI score (erythema, scaling, thickness), ear thickness, body weight, spleen index, IL-17A levels (ELISA/qPCR), skin histopathology (HE scoring for acanthosis, parakeratosis, inflammatory infiltration), optional: immunohistochemistry, flow cytometry |
| Positive control | Dexamethasone or anti-IL-17 antibody available as reference compounds |
| Data package | Raw data, analysis reports, clinical scores, histology slides, ELISA results, bioinformatics (optional) |
Q: What are the differences between IMQ and IL-23 induced psoriasis models?
A: IMQ activates TLR7/8, inducing IFN-α and downstream Th17 responses, mimicking the early phase of psoriasis. IL-23 directly activates γδ T cells and Th17 cells, more specifically targeting the IL-23/IL-17 axis central to chronic plaque psoriasis. Combination models provide enhanced severity and better recapitulate human disease.
Q: Which strain is best for psoriasis studies?
A: C57BL/6 mice are most commonly used for genetic studies and transgenic models. BALB/c mice exhibit stronger Th2 responses and are suitable for certain mechanistic studies. Wistar rats provide larger skin area for topical applications and histopathology.
Q: Can these models be used for IND-enabling studies?
A: Yes. Studies can be conducted in accordance with GLP principles for regulatory submissions (FDA, EMA).
Q: Do you offer customized study protocols (e.g., different IMQ doses, IL-23 administration routes)?
A: Absolutely. Our scientific team tailors induction protocols, treatment schedules, and endpoint analyses to your specific drug candidate.
Q: What is the typical timeline for a pilot efficacy study?
A: IMQ models typically run 5–7 days; IL-23 models run 3–7 days; combination models may extend to 10–14 days.
